Alnylam Pharmaceuticals (ALNY) Stock Price
$461.2 0%
to add to portfolio
AI Score
-
Alternative
8 -
Fundamental
5 -
Technical
7
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals. Scores are designed to reflect relative strength or weakness across these factors, helping users compare companies and track changes over time.
Sign up to get access to more historical data and insights on Alnylam Pharmaceuticals, AI stock picks, stock alerts and much more.
ALNY AI Stock Analysis
Financial Performance
The financial performance of Alnylam Pharmaceuticals has shown some negative trends in the last quarter. Revenue was reported at $500.9M, showing a decrease by -24.1% from the previous quarter. Gross profit also decreased by -29.8%, standing at $415M, and operating income showed a significant drop of -258.2%, with a loss of -$76.9M. The EBITDA ratio was negative at -0.12, indicating that operating expenses are higher than its earnings.
Stock Price
The stock price is currently trading at $255.28, which shows an increase of 4% in the last month and an impressive growth of 32% year over year compared to the stock's 200-day moving average of $226.56. However, it's important to note that the PE ratio is quite high at -97.44 and the EPS stands at -2.62, suggesting potential overvaluation.
Alternative Data Signals
In terms of alternative data signals, web traffic for Alnylam Pharmaceuticals has slightly decreased by -5.3% month over month but still maintains a decent volume with approximately 55958 visitors per month which indicates sustained interest in the company's activities or products/services among internet users.
The number of job openings has decreased both monthly (-4.3%) and yearly (-22%), possibly indicating restructuring or cost-saving measures within the company.
About two-thirds (66%) employees report having a positive business outlook which is up by +3% from last month but down yearly by -12%. This could suggest mixed sentiments about future prospects within the organization.
Social media followership on Twitter (+1%), Instagram (+38.6%), and Facebook (+124.8%) have all increased over the last 90 days, indicating growing public interest or engagement with the company.
Conclusion
The analysis of Alnylam Pharmaceuticals' stock performance is neutral to slightly bullish due to positive year-over-year stock price growth and social media engagement but tempered by recent declines in financial performance indicators and employee business outlook.
Note: This AI Stock Analysis is based on data as of January 13. Our members can refresh and get access to an up-to-date AI stock analysis.
Sign up
Alnylam Pharmaceuticals (ALNY) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Alnylam Pharmaceuticals (ALNY), currently trading at $461.2, will... Sign up to access price prediction.
About ALNY
-
Alnylam Pharmaceuticals, Inc.
-
Symbol
ALNY
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
60.5B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$20.07 1.6% |
8 |
 |
Inovio Pharmaceuticals INO |
$2.28 0.00% |
2 |
 |
Moderna MRNA |
$24.84 4% |
4 |
 |
Anavex Life Sciences AVXL |
$8.96 1.4% |
5 |
 |
BridgeBio Pharma BBIO |
$51.49 0% |
6 |
News
ALNY Alternative Data
Web Traffic
Alnylam Pharmaceuticals receives an estimated 65439 monthly visitors to alnylam.com.
-
Web Traffic
65439
-
Change from Previous Month
16.8%
-
3 Month Change
19.9%
-
YoY Change
19.9%
Twitter Followers
Alnylam Pharmaceuticals has 17,225 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.2% over the last month.
-
Twitter Followers
17225
-
Daily Change
0%
-
1 Month Change
0.2%
-
3 Month Change
0.7%
-
YoY Change
0.7%
Facebook Engagement
Alnylam Pharmaceuticals has engaged 14 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
14
-
Daily Change
0%
-
1 Month Change
88.1%
-
3 Month Change
95.3%
-
YoY Change
95.3%
Youtube Subscribers
Alnylam Pharmaceuticals has 2,740 subscribers on its main Youtube channel, up by 1.1% over the last month.
-
Youtube Subscribers
2740
-
Daily Change
0.4%
-
1 Month Change
1.1%
-
3 Month Change
2.6%
-
YoY Change
2.6%
LinkedIn Followers
248,523 are following Alnylam Pharmaceuticals on LinkedIn, up by 1.7% over the last month.
-
LinkedIn Followers
248523
-
Daily Change
0.1%
-
1 Month Change
1.7%
-
3 Month Change
4.9%
-
YoY Change
4.9%
Job Postings
Alnylam Pharmaceuticals currenly has an estimated 191 open job postings, up by 67.5% over the last month.
-
Job Postings
191
-
Daily Change
0%
-
1 Month Change
67.5%
-
3 Month Change
96.9%
-
YoY Change
96.9%
LinkedIn Employees
According to LinkedIn, Alnylam Pharmaceuticals has 2,613 employees, up by 0.7% over the last month.
-
LinkedIn Employees
2613
-
Daily Change
0%
-
1 Month Change
0.7%
-
3 Month Change
2.4%
-
YoY Change
2.4%
Reddit Mentions
Alnylam Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Instagram Followers
Alnylam Pharmaceuticals has 2,180 Instagram Followers on its main Instagram account, up by 3.1% over the last month.
-
Instagram Followers
2180
-
Daily Change
0.2%
-
1 Month Change
3.1%
-
3 Month Change
7.5%
-
YoY Change
7.5%
Business Outlook
According to employee reviews, the business outlook among employees at Alnylam Pharmaceuticals is 78 out of 100 (bullish).
-
Business Outlook
78
-
Change from Previous Month
2.6%
-
3 Month Change
1.3%
-
YoY Change
1.3%
News Mentions
Alnylam Pharmaceuticals was mentioned 3 times in the news yesterday.
-
News Mentions
3
-
Daily Change
50%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
ALNY Financials
ALNY Key Metrics
-
Total Revenue
$594.2M
-
Net Income
-$57.5M
-
Earnings per Share
-$0.44
-
Free cash flow
-$127.3M
-
EBITDA
$11.5M
-
EBITDA Ratio
0.0192784
-
Total Assets
$4.2B
ALNY 2-year Revenue & Income
ALNY 2-year Free Cash Flow
ALNY Technicals
ALNY SMA
ALNY RSI
FAQ
What's the current price of Alnylam Pharmaceuticals (ALNY) Stock?
The price of an Alnylam Pharmaceuticals (ALNY) share is $461.2.
What's the market cap of Alnylam Pharmaceuticals?
The current market cap of Alnylam Pharmaceuticals is 60.5B.
What are some stocks similar to Alnylam Pharmaceuticals (ALNY) that investors often compare it to?
Alnylam Pharmaceuticals (ALNY) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Alnylam Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Alnylam Pharmaceuticals' stock price to be around $492.1 in 2026. Starting from the current price of $461.2, this represents a 6.7% change in price, indicating a bullish outlook for the stock.
How to buy Alnylam Pharmaceuticals (ALNY) Stock?
Alnylam Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Alnylam Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.